Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.48 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052689 | 0.88 | GPR119 (0.51) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL31160618 | 0.85 | GPR119 (0.50) | GPR119KDM4EPKMCSF1R | |
| SCHEMBL791854 | 0.84 | KDM4E (0.55) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL1056543 | 0.84 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL19610219 | 0.84 | GPR119 (0.45) | GPR119SLC2A1KDM4EPKMCSF1R | |
| SCHEMBL1055480 | 0.84 | GPR119 (0.51) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL25577365 | 0.84 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL21644472 | 0.82 | ALDH1A1 (0.50) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL17078731 | 0.82 | GPR119 (0.56) | GPR119SLC2A1CHEK2KDM4EPKM | |
| SCHEMBL19610328 | 0.81 | GPR119 (0.45) | GPR119SLC2A1KDM4EPKMCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | ALK, MALT1, BCL6 | PDE4B 2261/4885PDE4A 2179/4885PDE4C 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.